Harlan S. Robins, who serves as Chief Scientific Officer at Adaptive Biotechnologies (NASDAQ:ADPT), executed a sale of 10,000 shares of the company's common stock on April 8, 2026, generating total proceeds of $148,500.
The transactions were completed in multiple tranches at prices ranging from $14.65 to $15.06 per share. Following these sales Robins is reported to directly own 1,512,058 shares of Adaptive Biotechnologies.
The disposition took place under a Rule 10b5-1 trading plan that Robins adopted on August 11, 2025. The timing of the sale preceded a notable move lower in ADPT shares; the stock is currently trading at $12.79, reflecting an approximate 14% decline over the last week.
According to InvestingPro analysis, ADPT is trading above its Fair Value and is included on the Most Overvalued list maintained by that research service. Investors interested in additional detail are directed to ADPT's Pro Research Report, which InvestingPro makes available alongside coverage of more than 1,400 other U.S. equities.
In a separate set of company-specific developments, Adeptus Biotechnologies Corp reported fourth-quarter 2025 results that exceeded analyst expectations. The company posted earnings per share of -$0.09, versus an anticipated -$0.18, representing a 50% positive surprise relative to the forecast. Revenue for the quarter totaled $71.7 million, above the consensus estimate of $59.33 million by roughly 20.85%.
Following those results, several brokerages adjusted their outlooks on Adeptus Biotechnologies Corp. BTIG raised its price target to $22.00, citing strong growth in the company's Minimal Residual Disease (MRD) business, which grew 54% year-over-year in Q4 2025. TD Cowen increased its price target to $21.00 while retaining its prior rating, and Piper Sandler reiterated an Overweight rating, pointing to the company's MRD positioning and projected volume expansion.
The facts presented here are confined to reported transactions, stated ownership after the sale, the disclosed 10b5-1 plan adoption date, current share price and recent price movement, InvestingPro's Fair Value classification, and the cited fourth-quarter 2025 financial results and subsequent broker reactions for Adeptus Biotechnologies Corp. No additional implications beyond those reported are asserted.